Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 140 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Huntingtons Disease Clear all
Not listed Phase 1 Interventional

Ursodiol in Huntington's Disease

NCT00514774
View directory record Official record
Conditions
Huntington Disease
Interventions
ursodiol, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Not applicable Interventional

Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease

NCT02268617
View directory record Official record
Conditions
Huntington Disease, Lewy Body Disease
Interventions
Treadmill Walking
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Jul 23, 2026, 1:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease

NCT07451613
View directory record Official record
Conditions
Huntington Disease
Interventions
hNSC-01
Biological
Lead sponsor
Leslie Thompson
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Nutritional Supplement Effect on HDL Function

NCT04529174
View directory record Official record
Conditions
HDL
Interventions
CardioLux™HDL, Placebo
Dietary Supplement
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jul 23, 2026, 1:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Huntington At Risk Observational Study

NCT00052143
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
Huntington Study Group
Network
Eligibility
26 Years to 55 Years
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Jul 23, 2026, 1:30 AM EDT
Recruiting Not applicable Interventional

Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease

NCT06843252
View directory record Official record
Conditions
Huntington Disease
Interventions
Transcranial direct current stimulation (tDCS), Sham tDCS
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 23, 2026, 1:30 AM EDT
Active, not recruiting Not applicable Interventional

Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers

NCT05596760
View directory record Official record
Conditions
Dementia, Dementia, Vascular, Mixed Dementias, Alzheimer Disease, Huntington Disease, Lewy Body Disease, Creutzfeldt-Jakob Syndrome, Frontotemporal Lobar Degeneration, Cognitive Dysfunction, Cognitive Aging, Chronic Disease, Palliative Care, Patient Care, Health Care Quality, Access, and Evaluation, Patient Care, Health Communication, Patient Care Planning, Quality of Life
Interventions
Jumpstart Guide
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 1 Interventional

Bioavailability of Ubiquinol in Huntington Disease

NCT00980694
View directory record Official record
Conditions
Huntington Disease
Interventions
ubiquinol
Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional

Creatine Therapy for Huntington's Disease

NCT00026988
View directory record Official record
Conditions
Huntington's Disease
Interventions
Creatine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
Boston, Massachusetts • Long Island City, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jul 23, 2026, 1:30 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

NCT07010705
View directory record Official record
Conditions
Huntington Disease, Healthy
Interventions
ActiGraph LEAP, Axivity AX6
Device
Lead sponsor
University of Rochester
Other
Eligibility
25 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 23, 2026, 1:30 AM EDT
Not listed Not applicable Interventional

PHysical Activity and Exercise Outcomes in Huntington's Disease

NCT03344601
View directory record Official record
Conditions
Huntington Disease
Interventions
physical activity
Behavioral
Lead sponsor
Cardiff University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 4 Interventional Results available

Study of Memantine to Treat Huntington's Disease

NCT00652457
View directory record Official record
Conditions
Huntington's Disease
Interventions
Memantine
Drug
Lead sponsor
Jody Corey-Bloom, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
La Jolla, California • Kansas City, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 2 Interventional

An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

NCT04514367
View directory record Official record
Conditions
Huntington Disease
Interventions
ANX005
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Birmingham, Alabama • Englewood, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 2 Interventional

Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability

NCT01411163
View directory record Official record
Conditions
Huntington's Disease
Interventions
Creatine monohydrate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
26 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Jul 23, 2026, 1:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 23, 2026, 1:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

NCT01860339
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
Peggy C Nopoulos
Other
Eligibility
6 Years to 30 Years
Enrollment
488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2026
U.S. locations
6
States / cities
Sacramento, California • Iowa City, Iowa • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

NCT00931073
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2009 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

NCT03854019
View directory record Official record
Conditions
Huntington Disease, Irritability
Interventions
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 3 Interventional

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

NCT04400331
View directory record Official record
Conditions
Chorea, Huntington
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 1:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Complex Eye Movements in Parkinson's Disease and Related Movement Disorders

NCT04925622
View directory record Official record
Conditions
Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonian Disorders, Essential Tremor, Vascular Parkinsonism, Multiple System Atrophy, Parkinson Variant, Parkinsonian Syndrome, Huntington Disease
Interventions
Complex eye movement exam
Diagnostic Test
Lead sponsor
Saccadous, Inc.
Other
Eligibility
30 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

NCT03761849
View directory record Official record
Conditions
Huntingtons Disease
Interventions
RO7234292, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 65 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Jul 23, 2026, 1:30 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

NCT03842969
View directory record Official record
Conditions
Huntington Disease
Interventions
RO7234292 (RG6042)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Jul 23, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

NCT05358717
View directory record Official record
Conditions
Huntington Disease
Interventions
PTC518, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
25 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
La Jolla, California • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 1:30 AM EDT